Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study-Reference-Cited by-同舟云学术

Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study

Published:2022-07 Issue:7 Volume:3 Page:e481-e490
ISSN:2666-7568
Container-title:The Lancet Healthy Longevity
language:en
Short-container-title:The Lancet Healthy Longevity

Author:

Xu Peng-Peng,Shi Zi-Yang,Qian Ying,Cheng Shu,Zhu Yue,Jiang Lu,Li Jian-Feng,Fang Hai,Huang Heng-Ye,Yi Hong-Mei,Ouyang Bin-Sheng,Wang Li,Zhao Wei-Li

Funder

Shanghai Hospital Development Center

National Natural Science Foundation of China

Shanghai Municipal Education Commission

School of Medicine, Shanghai Jiao Tong University

Publisher

Elsevier BV

Subject

Family Practice,Psychiatry and Mental health,Geriatrics and Gerontology,Health (social science)

Reference30 articles.

1. Diffuse large B-cell lymphoma;Sehn;N Engl J Med,2021

2. Incidence and survival of hematological cancers among adults ages ≥75 years;Krok-Schoen;Cancer Med,2018

3. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial;Peyrade;Lancet Oncol,2011

4. Diffuse large B-cell lymphoma in the elderly: standard treatment and new perspectives;Chiappella;Expert Rev Hematol,2017

5. Oncogenic mutations and tumor microenvironment alterations of older patients with diffuse large B-cell lymphoma;Zhu;Front Immunol,2022

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature;Hematology Reports;2024-05-24

2. A single‐centre, real‐world study of BTK inhibitors for the initial treatment of MYD88^mut/CD79B^mut diffuse large B‐cell lymphoma;Cancer Medicine;2024-02

3. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies;Journal of Medicinal Chemistry;2024-02-01

4. Curative intent therapy for DLBCL in the elderly;Leukemia & Lymphoma;2024-01-11

5. Specific aspects of prognosis and treatment of elderly patients with large B-cell lymphoma;Medicinska istrazivanja;2024